LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Inicio・Lista de Acciones・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Cerrado

SectorSanidad

27.71 2.21

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

27.02

Máximo

27.79

Métricas clave
By Trading Economics
Ingresos	-547M -179M
Ventas	-515M 28M
Margen de beneficios	-643.397
Empleados	609
EBITDA	-563M -166M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+31.28% upside

Dividendos
By Dow Jones
Próximas Ganancias	25 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	771M 3B
Apertura anterior	25.5
Cierre anterior	27.71

Noticias sobre sentimiento de mercado

By Acuity

94%

8 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

11.5 / 12.23 Soporte y Resistencia

Arrowhead Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2025, 23:37 UTC

Acciones populares

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept 2025, 20:41 UTC

Ganancias

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept 2025, 20:30 UTC

Ganancias

GameStop 2Q Sales, Profit Rise

9 sept 2025, 23:19 UTC

Charlas de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept 2025, 21:35 UTC

Ganancias

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 21:32 UTC

Ganancias

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 sept 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept 2025, 20:26 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:23 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:12 UTC

Ganancias

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept 2025, 20:07 UTC

Ganancias

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Rev $14.93B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q EPS $1.01 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Synopsys 3Q EPS $1.50 >SNPS

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Hardware Revenue $670M >ORCL

Comparación entre iguales

Cambio de precio

Arrowhead Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

31.28% repunte

Estimación a 12 Meses

Media 35.67 USD 31.28%

Máximo 80 USD

Mínimo 12 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arrowhead Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Arrowhead Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

11.5 / 12.23Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentimiento

By Acuity

8 / 371 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.